Pathfinders in Biopharma

46 Episodes

1. ECM: Robust End to Year, Despite Previous Volatility

   Published: 10/31/2023
2. Biotech Halftime Report: A Winding Road Ahead

   Published: 9/26/2023
3. The Urgent Need to Address the Youth Mental Health Landscape

   Published: 8/17/2023
4. Website Traffic Reveals Biopharma Sales Trends

   Published: 8/7/2023
5. When to Call it Quits: VCs Making Tough Decisions in a Tough Market

   Published: 7/13/2023
6. How Biotech M&A is Redefining the Strategic Landscape

   Published: 6/23/2023
7. Healthcare Should Get Ready for ‘Fast and Furious’ M&A

   Published: 6/8/2023
8. Innovation and Growth: Key Ingredients to Healthcare M&A

   Published: 6/7/2023
9. Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?

   Published: 6/2/2023
10. Global Blood Therapeutics Commitment to Sickle-Cell Innovation

    Published: 5/22/2023
11. Is This the Breakthrough Moment for Genetic Medicine?

    Published: 4/13/2023
12. The Hidden Revolution Set to Turn US Healthcare on its Head

    Published: 1/26/2023
13. The Big Picture for Biotech

    Published: 12/13/2022
14. Why Biopharma Investment Requires a Different Mindset

    Published: 11/22/2022
15. The Optimism Behind the Biopharma Market

    Published: 10/3/2022
16. Biotech Investors: How to Find Value in a Bear Market

    Published: 3/21/2022
17. A call to action: Global Blood Therapeutics on tackling orphan disease

    Published: 12/8/2021
18. Ionis: Raising The Bar For ESG

    Published: 10/28/2021
19. Biotech and Big Pharma: Blueprint for Successful Partnership

    Published: 9/30/2021
20. What’s Material in ESG for Biopharma Firms?

    Published: 5/4/2021